129 related articles for article (PubMed ID: 3422419)
1. Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system.
Lorand L; Velasco PT; Rinne JR; Amare M; Miller LK; Zucker ML
Proc Natl Acad Sci U S A; 1988 Jan; 85(1):232-6. PubMed ID: 3422419
[TBL] [Abstract][Full Text] [Related]
2. Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder.
Lopaciuk S; Bykowska K; McDonagh JM; McDonagh RP; Yount WJ; Fuller CR; Cooperstein L; Gray A; Lorand L
J Clin Invest; 1978 May; 61(5):1196-203. PubMed ID: 96136
[TBL] [Abstract][Full Text] [Related]
3. A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA.
Fukue H; Anderson K; McPhedran P; Clyne L; McDonagh J
Blood; 1992 Jan; 79(1):65-74. PubMed ID: 1370210
[TBL] [Abstract][Full Text] [Related]
4. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII).
Lorand L; Maldonado N; Fradera J; Atencio AC; Robertson B; Urayama T
Br J Haematol; 1972 Jul; 23(1):17-27. PubMed ID: 5045959
[No Abstract] [Full Text] [Related]
5. Generation and mechanism of action of a potent inhibitor of factor XIII function.
Reed GL; Lukacova D
Thromb Haemost; 1995 Aug; 74(2):680-5. PubMed ID: 8585006
[TBL] [Abstract][Full Text] [Related]
6. Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against actor XIII.
Lorand L; Velasco PT; Hill JM; Hoffmeister KJ; Kaye FJ
Thromb Haemost; 2002 Dec; 88(6):919-23. PubMed ID: 12529739
[TBL] [Abstract][Full Text] [Related]
7. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide.
Tosetto A; Rodeghiero F; Gatto E; Manotti C; Poli T
Am J Hematol; 1995 Jan; 48(1):34-9. PubMed ID: 7832189
[TBL] [Abstract][Full Text] [Related]
8. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide.
Nakamura S; Kato A; Sakata Y; Aoki N
Br J Haematol; 1988 Mar; 68(3):313-9. PubMed ID: 3258529
[TBL] [Abstract][Full Text] [Related]
9. Acquired plasma factor XIII deficiencies.
Tosetto A; Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):5-10. PubMed ID: 8039759
[TBL] [Abstract][Full Text] [Related]
10. Aggressive fatal case of autoimmune hemorrhaphilia resulting from anti-Factor XIII antibodies.
Sugiyama H; Uesugi H; Suzuki S; Tanaka K; Souri M; Ichinose A
Blood Coagul Fibrinolysis; 2013 Jan; 24(1):85-9. PubMed ID: 23183237
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner.
Lorand L; Velasco PT; Murthy SN; Lefebvre P; Green D
Blood; 1999 Feb; 93(3):909-17. PubMed ID: 9920840
[TBL] [Abstract][Full Text] [Related]
12. An inhibitor of activated factor XIII, inhibiting fibrin cross-linking but not incorporation of amine into casein.
Godal HC; Ly B
Scand J Haematol; 1977 Nov; 19(5):443-8. PubMed ID: 594661
[TBL] [Abstract][Full Text] [Related]
13. Rapid immunochromatographic test for detection of anti-factor XIII A subunit antibodies can diagnose 90 % of cases with autoimmune haemorrhaphilia XIII/13.
Osaki T; Sugiyama D; Magari Y; Souri M; Ichinose A
Thromb Haemost; 2015 Jun; 113(6):1347-56. PubMed ID: 25740658
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic autoantibody that inhibits fibrin monomer polymerization.
Ghosh S; McEvoy P; McVerry BA
Br J Haematol; 1983 Jan; 53(1):65-72. PubMed ID: 6848127
[TBL] [Abstract][Full Text] [Related]
15. Severe bleeding diatheses in an elderly patient with combined type autoantibody against factor XIII A subunit; novel approach to the diagnosis and classification of anti-factor XIII antibodies.
Kun M; Szuber N; Katona É; Pénzes K; Bonnefoy A; Bécsi B; Erdődi F; Rivard GE; Muszbek L
Haemophilia; 2017 Jul; 23(4):590-597. PubMed ID: 28345289
[TBL] [Abstract][Full Text] [Related]
16. Successful Management of a Patient with Autoimmune Hemorrhaphilia due to Anti-Factor XIII/13 Antibodies Complicated by Pulmonary Thromboembolism.
Ogawa Y; Yanagisawa K; Souri M; Mihara M; Naito C; Takizawa M; Ishizaki T; Mitsui T; Handa H; Osaki T; Nojima Y; Ichinose A
Acta Haematol; 2017; 137(3):141-147. PubMed ID: 28380473
[TBL] [Abstract][Full Text] [Related]
17. An acquired inhibitor of factor XIII with a qualitative abnormality of fibrin cross-linking.
Fear JD; Miloszewski KJ; Losowsky MS
Acta Haematol; 1984; 71(5):304-9. PubMed ID: 6429995
[TBL] [Abstract][Full Text] [Related]
18. Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus.
Ahmad F; Solymoss S; Poon MC; Berube C; Sullivan AK
Br J Haematol; 1996 Jun; 93(3):700-3. PubMed ID: 8652397
[TBL] [Abstract][Full Text] [Related]
19. Investigation of a link between raised levels of pepsinogen in blood as a mediator of in-vitro clot lysis in acid and a cause of abnormal factor XIII screening tests.
Duncan EM; Dale BJ; Lloyd JV
Blood Coagul Fibrinolysis; 2014 Jun; 25(4):340-8. PubMed ID: 24440916
[TBL] [Abstract][Full Text] [Related]
20. An IgG inhibitor against coagulation factor XIII: resolution of bleeding after plasma immunoadsorption with staphylococcal protein A.
Gailani D
Am J Med; 1992 Jan; 92(1):110-2. PubMed ID: 1731502
[No Abstract] [Full Text] [Related]
[Next] [New Search]
